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Abstract
The use of chitosan microparticles as injectable carriers for cell transplantation represents a
promising alternative to avoid the drawbacks of the implantation of other forms of three-dimensional
(3D) scaffolds seeded with cells. In this study, a 3D construct is obtained in vitro by combining
chitosan microparticles crosslinked with genipin and goat bone marrow stromal cells (GBMCs). Cell
viability and the morphology of GBMCs were evaluated after culture for 7 and 14 days. Our results
show the feasibility of chitosan microparticles as potential injectable scaffolds for tissue engineering
and regenerative medicine. Copyright  2008 John Wiley & Sons, Ltd.
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Tissue engineering has progressed from the use of
biomaterials, as a possible therapy for damaged tissue
and organs (Langer and Vacanti 1993). Several studies
have focused on seeding cells onto three-dimensional
(3D) porous scaffolds in the form of hydrogels (Lee
and Mooney, 2001), sponges (Tsang and Bhatia, 2004;
Escobar et al., 2007), fibers (Chew et al., 2008), meshes
(Tuzlakoglu et al., 2004; Rodriguez et al., 2008) or films
(Costa et al., 2007; da Silva, 2007) in order to guide tissue
regeneration.
Recently, microspheres have also been assessed as
scaffold for tissue engineering and new strategies, such
as sintering (Borden et al., 2002) and fusion (Malafaya
et al., 2005; Jaklenec et al., 2008) methods, have been
investigated to obtain suitable scaffolds that mimic the
tissue environment for cells (Silva et al., 2007; Curran
et al., 2005). Most of the concepts based on the use of
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such scaffolds require the implantation kind of the hybrid
constructs through a surgical procedure.
In this work, our goal is to combine isolated particles
and cells previously incubated on their surface as a
potential alternative in the context of a minimally
invasive strategy, as one expects that the particles might
agglomerate after implantation as a consequence of cell
proliferation and extracellular matrix production playing
the role of the 3D scaffold.
Chitosan has been used in the production of scaffolds
for tissue engineering (Tuzlakoglu et al. 2004; Oliveira
et al. 2006); simultaneously, chitosan particles have
been also proposed to be used for the delivery of
therapeutic molecules (Prabaharan and Mano, 2005).
We will use this system to prove the above-mentioned
concept. Chitosan microparticles were prepared by an
emulsion crosslinking technique (Denkbas et al., 1999;
Al-Helw et al., 1998). Briefly, 2 wt% chitosan solution in
acetic acid 1% v/v was added to mineral oil, containing
a surfactant (Tween 80) to form the w/o emulsion.
Genipin, a molecules extracted from the fruits of Gardenia
jasminoides Ellis was used as the crosslinking agent
Copyright  2008 John Wiley & Sons, Ltd.
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(Butler et al., 2003) at different concentrations (20 or
40 mM). Emulsion was stirred overnight for 17 h and
the crosslinked chitosan microparticles were recovered
by centrifugation. The morphological, surface appearance
and the size of crosslinked chitosan microparticles were
examined by optical microscopy (Figure 1) showing dark-
bluish coloured spherical particles with very smooth
surface. The microsphere diameter was 70± 20 µm and
60± 10 µm for crosslinked particles with 20 and 40 mM
genipin, respectively. The colour was deepened with the
increase of genipin concentration and bluish colour was
attributed to double bonds in the genipin crosslinking
molecules.
To analyse the biological response, goat bone mar-
row stromal cells (GBMCs) were seeded on chitosan
microparticles and cultured for 7 and 14 days. Cell via-
bility and proliferation, as evaluated by the MTS assay
(Figure 2), demonstrate that the studied chitosan pro-
vided an adequate environment for cell attachment and
growth. Viability was higher for cell cultures with chitosan
microparticles crosslinked with genipin solution 20 mM
than 40 nM (Figure 2). The crosslinking with genipin is
produced through amine bonds and therefore a higher
number of free amine groups is expected to appear at the
surface of the less cross-linked microsphere, which could
enhance cell attachment and consequently cell viability.
Cell morphology evaluated by SEM (Figure 3) demon-
strated that after 7 days of culture the cells attached
and grew favourably on the microparticles, forming
interparticulate cellular bridges and small cell–particle
aggregates. Note that cells are in the order of magni-
tude or bigger than microspheres. Cells spread actively
extending filopodia that adhere on a number of substrate
particles. It can be said that on the one hand cell allow
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Figure 2. MTS assay performed on chitosan microparticles
cultured with GBMCs. Data represented are mean ± SD.
∗p < 0.05
microparticles to join together and on the other hand it is
precisely this cell–microparticle spatial arrangement what
allows chitosan to play the role of a 3D scaffold that sur-
rounds cells. Besides, unlike conventional scaffolds, this
system is highly dynamic in nature and microparticles
will be displaced during cell growth, allowing the natural
expansion of the tissue. Non-treated chitosan particles
were used in this work for the proof of concept. However,
new possibilities are open to broaden this concept. For
example, combination of different kinds of particles, made
of different materials or with more complex size distribu-
tion, could be used; moreover, the surface of the particles
could be easily modified or a wide range of therapeutical
molecules, including soluble factors, could be encapsu-
lated in order to control cell adhesion, differentiation and
proliferation.
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Figure 1. Morphology of chitosan microparticles cross-linked with a solution of 20 mM (A) and 40 mM (B) genipin. Their respective
microparticle diameter histograms are represented in (C) and (D)
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Figure 3. SEM microphotographs of GBMCs on chitosan microparticles. (A, B) Images correspond to crosslinked microparticles
with 20 and 40 mM genipin, respectively; the subindices represent 7 and 14 days of culture
In conclusion, genipin-crosslinked chitosan micro-
spheres support GBMCs adhesion and proliferation with-
out the need of any specific surface treatment. Cells
spread on the surface of the microspheres joining them to
form a 3D construct in which microparticles play the role
of the scaffold. Crosslinking density affects cell viability
slightly but significantly. Such systems could be used in
tissue-engineering strategies involving minimally invasive
procedures to deliver a combination of cell, growth factors
and supporting material.
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